Skip to content
Clinical Trials – home

PHLEUM PRATENSE POLLEN EXTRACT (Grastek®): A Treatment for Grass Pollen Allergies

3 / 5
trials open to patients / all trials
3+
Countries

In short

This article discusses a clinical trial investigating the use of Grastek®, a sublingual immunotherapy containing Phleum Pratense (Timothy grass) pollen extract, for treating allergic rhinoconjunctivitis. The study aims to evaluate the potential benefits of Grastek® in managing symptoms related to birch pollen allergies, even though it is primarily designed for grass pollen allergies. This pilot study involves a controlled environment and compares the effects of Grastek® to a placebo over a four-month treatment period.

At a glance

Study Type
Phase IV, single center, placebo-controlled, parallel design
Medication
Grastek® (Phleum Pratense Pollen Extract)
Condition
Allergic Rhinoconjunctivitis (focusing on birch pollen-induced)
Participants
96 (48 receiving Grastek®, 48 receiving placebo)
Treatment Duration
120 days (4 months)
Dosage
One tablet daily (2800 BAU of Timothy grass extract)
Primary Outcome
Change in Total Nasal Symptom Score (TNSS)
Secondary Outcome
Analysis of blood samples for potential biomarkers
Study Environment
Environmental Exposure Unit (EEU) for controlled pollen exposure

What is Grastek®?

Grastek® is a medication used to treat allergies caused by grass pollen. It contains an extract from Timothy grass (Phleum pratense) pollen, which is why it's called a Phleum pratense pollen extract. This medication is a type of treatment known as sublingual immunotherapy (SLIT), which means it's taken by placing a tablet under the tongue.

How Grastek® Works

Grastek® works by gradually exposing your body to small amounts of grass pollen. Over time, this exposure helps your immune system become less sensitive to grass pollen, reducing your allergic reactions when you encounter it in the environment. This process is called desensitization.

Conditions Treated by Grastek®

Grastek® is specifically designed to treat allergic rhinoconjunctivitis caused by grass pollen. This condition includes symptoms such as:

  • Runny nose: Excessive nasal discharge
  • Itchy nose: An irritating sensation inside the nose
  • Sneezing: Sudden, forceful expulsion of air through the nose and mouth
  • Nasal congestion: A stuffy or blocked feeling in the nose
  • Eye symptoms: Such as itchy, watery, or red eyes

How Grastek® is Administered

Grastek® is taken as a tablet that dissolves under the tongue. In clinical studies, patients took one tablet daily for four months. It's important to follow your doctor's instructions precisely when taking this medication.

Clinical Study on Grastek®

A clinical trial was conducted to evaluate the effectiveness of Grastek® in treating allergic rhinoconjunctivitis. This study, named NCT02394600, was designed as follows:

  • Type of study: Phase IV, single center, placebo-controlled, parallel study
  • Number of participants: 96
  • Duration of treatment: 120 days (4 months)
  • Groups: Participants were divided into two groups:
    • 48 participants received Grastek®
    • 48 participants received a placebo (a sugar pill with no active ingredients)

Effectiveness of Grastek®

The main measure of effectiveness in the study was the change in Total Nasal Symptom Score (TNSS) from the beginning to the end of treatment. The TNSS measures four main symptoms of allergic rhinitis:

  1. Runny nose
  2. Itchy nose
  3. Sneezing
  4. Nasal congestion

Each symptom is rated on a scale from 0 (no symptoms) to 3 (severe symptoms), resulting in a total score range of 0 to 12. A decrease in TNSS after treatment would indicate that Grastek® is effective in reducing allergy symptoms.

Potential Benefits of Grastek®

While the study primarily focused on grass pollen allergies, researchers were also interested in whether Grastek® might have benefits for people with birch pollen allergies. This suggests that Grastek® might potentially help with multiple types of pollen allergies, though more research is needed to confirm this.

Additionally, the study aimed to identify potential biomarkers that could predict how well a person might respond to Grastek® treatment. Biomarkers are measurable indicators in the body (often found in blood samples) that can provide information about a person's health or response to treatment.

Questions people often ask

Conditions where Phleum Pratense Pollen Extract is being studied

Each condition opens its own overview and trial list

Trials with Phleum Pratense Pollen Extract

Recruiting trials first

See all 5 →
Quick filters
  • Participants:All ages
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.